BiotechTube
Home/Pipeline/Generics Pipeline

Generics Pipeline

Various

ANDA Filed/DevelopmentActive

Key Facts

Indication
Various
Phase
ANDA Filed/Development
Status
Active
Company
ANI Pharmaceuticals

About ANI Pharmaceuticals

ANI Pharmaceuticals has evolved from a generic drug manufacturer into a diversified biopharmaceutical company with a three-pillar strategy: Rare Disease, Generics, and Established Brands. A key achievement was the transformative acquisition of Novitium Pharma, which significantly expanded its R&D capabilities, manufacturing footprint, and specialty portfolio. Under CEO Nikhil Lalwani, the company is focused on delivering sustainable growth by commercializing novel therapies for underserved patient populations while maintaining the stable cash flows of its legacy businesses.

View full company profile

Therapeutic Areas

OphthalmologyRheumatologyNephrologyNeurologyPulmonology

Other Various Drugs

DrugCompanyPhase
New Generic ApprovalsChina SXT PharmaceuticalsApplication Submitted / BE Stage
New Dosage Form DevelopmentUniverse PharmaceuticalsDevelopment
New TCM Formula RegistrationUniverse PharmaceuticalsDevelopment
Bag APIsChemWerthApproved
Oral APIsChemWerthApproved
Companion Diagnostics DevelopmentKiffik BiomedicalPre-clinical
Portfolio of Complex Generics & 505(b)(2) ProductsAlvogenApproved/Commercial
Portfolio of 40+ productsPraxgen PharmaceuticalsDevelopment
Generic Product PipelineLannettANDA Development
Drug Repositioning ServiceBiovistaService
Custom Control DevelopmentAnchor MolecularDevelopment/Commercial
Portfolio from Steriscience PartnershipArmas PharmaceuticalsANDA Development/Filing